© 2001 by European Society of Cardiology
Copyright © 2001, European Society of Cardiology
U-46619-induced potentiation of noradrenergic constriction in the human saphenous vein: antagonism by thromboxane receptor blockade
aDepartment of Physiology, University of Valencia School of Medicine, 46010 Valencia, Spain
bDepartment of Surgery, University of Valencia School of Medicine, 46010 Valencia, Spain
vila{at}post.uv.es
* Corresponding author. Departamento de Fisiología, Facultad de Medicina y Odontología, Blasco Ibáñez 17, 46010 Valencia, Spain. Tel.: +34-6-386-4644; fax: 34-6-386-4642
Objective: We investigated the potentiating effect of U-46619, a synthetic analogue of thromboxane A2 (TXA2), on the adrenergic responses in human saphenous vein. Methods: Saphenous vein rings were obtained from 35 patients undergoing coronary artery bypass surgery. The rings were suspended in organ bath chambers for isometric recording of tension. Results: U-46619 (10–10–3x10–7 mol/l) produced concentration-dependent and endothelium-independent contractile responses. U-46619 (10–10 mol/l) potentiated the contractions elicited by electrical stimulation and potassium chloride, and produced leftward shifts of the concentration–response curve for noradrenaline. The TXA2 receptor antagonist SQ-30741 (10–8 mol/l) prevented the potentiation evoked by U-46619. The dihydropyridine calcium antagonist nifedipine (10–6 mol/l) did not affect the potentiation of electrical stimulation and noradrenaline induced by U-46619, but abolished the potentiation of U-46619 on KCl-induced contractions. Conclusions: U-46619 facilitates sympathetic neurotransmission and potentiates constrictor effects of noradrenaline in human saphenous veins through stimulation of TXA2 receptors. These effects are independent of calcium entry through dihydropyridine calcium channels.
KEYWORDS Adrenergic (ant)agonists; Ca-channel; Receptors; Vasoconstriction/dilation; Veins; Endothelial factors; Vasoactive agents
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  R. Aras-Lopez, J. Blanco-Rivero, F. E. Xavier, M. Salaices, M. Ferrer, and G. Balfagon Dexamethasone Decreases Contraction to Electrical Field Stimulation in Mesenteric Arteries from Spontaneously Hypertensive Rats through Decreases in Thromboxane A2 Release J. Pharmacol. Exp. Ther., September 1, 2007; 322(3): 1129 - 1136. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Leineweber, D. Bose, M. Vogelsang, M. Haude, R. Erbel, and G. Heusch Intense Vasoconstriction in Response to Aspirate From Stented Saphenous Vein Aortocoronary Bypass Grafts J. Am. Coll. Cardiol., March 7, 2006; 47(5): 981 - 986. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Kobayashi, T. Matsumoto, and K. Kamata IGF-I-induced enhancement of contractile response in organ-cultured aortae from diabetic rats is mediated by sustained thromboxane A2 release from endothelial cells J. Endocrinol., August 1, 2005; 186(2): 367 - 376. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. A. Tanaka, F. Szlam, N. Katori, A. Tsuda, and J. H. Levy In vitro effects of antihypertensive drugs on thromboxane agonist (U46619)-induced vasoconstriction in human internal mammary artery Br. J. Anaesth., August 1, 2004; 93(2): 257 - 262. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.Y Jeremy and D.P Mikhailidis U-46619-induced potentiation of noradrenergic constriction in the human saphenous vein: antagonism by thromboxane receptor blockade Cardiovasc Res, June 1, 2002; 54(3): 701 - 701. [Full Text] [PDF]
|
|